ICON plc’s clinical research unit in San Antonio is now a certified site in iCardiac’s Early Precision QT Program, which enables ICON to offer iCardiac’s services for evaluating the cardiac safety of new compounds in Phase I trials. The services provide clients with an earlier assessment of the safety risk of their drug and potentially eliminates the need for a separate Thorough QT (TQT) study in later stages of development.   Since 2005, the FDA has required all new compounds in development t...